The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK.
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Birmingham, UK.
Bone Joint J. 2021 Sep;103-B(9):1541-1549. doi: 10.1302/0301-620X.103B9.BJJ-2020-2554.R1.
While a centralized system for the care of patients with a sarcoma has been advocated for decades, regional variations in survival remain unclear. The aim of this study was to investigate regional variations in survival and the impact of national policies in patients with a soft-tissue sarcoma (STS) in the UK.
The study included 1,775 patients with a STS who were referred to a tertiary sarcoma centre. The geographical variations in survival were evaluated according to the periods before and after the issue of guidance by the National Institute for Health and Care Excellence (NICE) in 2006 and the relevant evolution of regional management.
There had been a significant difference in survival between patients referred from the North East, North West, East Midlands, West Midlands, South West, and Wales in the pre-NICE era (five-year disease-specific survival (DSS); South West, 74% vs North East, 47% (p = 0.045) or West Midlands, 54% (p = 0.049)), which was most evident for patients with a high-grade STS. However, this variation disappeared in the post-NICE era, in which the overall DSS for high-grade STS improved from 47% to 68% at five years (p < 0.001). Variation in the size of the tumour closely correlated with the variation in DSS, and the overall size of the tumour and incidence of metastasis at the time of diagnosis also decreased after the national policies were issued.
The survival of patients with a STS improved and regional variation corrected after the introduction of national policies, as a result of a decreasing size of tumour and incidence of metastasis at the time of diagnosis, particularly in patients with a high-grade STS. This highlights the positive impact of national guidelines on regional variation in the presentation, management, and outcome in patients with a STS. Cite this article: 2021;103-B(9):1541-1549.
几十年来,人们一直倡导建立集中式系统来治疗肉瘤患者,但生存率的区域性差异仍不清楚。本研究旨在调查英国软组织肉瘤(STS)患者生存率的区域性差异,以及国家政策的影响。
该研究纳入了 1775 名转诊至三级肉瘤中心的 STS 患者。根据 2006 年国家卫生与保健卓越研究所(NICE)发布指南前后的时期以及区域管理的相关演变,评估了生存率的地理差异。
在 NICE 之前的时代,来自东北、西北、中东部、西米德兰兹、西南部和威尔士的患者之间的生存存在显著差异(五年疾病特异性生存率(DSS);西南部为 74%,东北为 47%(p = 0.045)或西米德兰兹为 54%(p = 0.049)),这在高级别 STS 患者中最为明显。然而,这种差异在 NICE 之后的时代消失了,高级别 STS 的总体五年 DSS 从 47%提高到 68%(p < 0.001)。肿瘤大小的变化与 DSS 的变化密切相关,而且在国家政策发布后,肿瘤的总体大小和诊断时转移的发生率也降低了。
由于诊断时肿瘤大小和转移发生率的降低,特别是在高级别 STS 患者中,国家政策的引入改善了 STS 患者的生存率,并纠正了区域性差异。这突显了国家指南对 STS 患者的表现、管理和结局的区域性差异的积极影响。引用本文:2021;103-B(9):1541-1549。